Drugs / ChAdOx1.HTI
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05208125 | Mar 2022 | HIV infectious disease | IrsiCaixa | Completed | No outcome recorded |
| Phase 1 | NCT04385875 | Jun 2020 → Aug 2021 | HIV infectious disease | Fight AIDS and Infectious Diseases Foundation | Completed | No outcome recorded |
| Phase 1 | NCT03204617 | Jul 2017 → Jul 2020 | HIV infectious disease | Aelix Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04563377 | Nov 2021 → Aug 2022 | — | University of Oxford | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04364035 | Feb 2020 → Oct 2022 | HIV infectious disease | Aelix Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOx1.HTI | “DNA.HTI at weeks 0, 4, and 8 and MVA.HTI at weeks 12 and 20 (DDDMM) followed by ChAdOx1.HTI at weeks 0 and 12 and MVA.HTI at week 24 (CCM)” NCT04385875 ↗ |
| Modality | Vaccine | “Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI or Placebo” NCT04385875 ↗ |
| Route | Intramuscular | “Vaccine delivered as one 0. 5 mL IM injection” NCT04364035 ↗ |